Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development Addex Therapeutics Ltd Bristol-Myers Squibb Co Eisai Co Ltd Eli Lilly and Co Hua Medicine Shanghai Ltd Johnson & Johnson Laboratorio Farmaceutico CT Srl Novartis AG Park Active Molecules Richter Gedeon Nyrt Sosei Heptares Sumitomo Dainippon Pharma Co Ltd Toray Industries Inc Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles alloswitch-1 - Drug Profile Product Description Mechanism Of Action R&D Progress arbaclofen - Drug Profile Product Description Mechanism Of Action R&D Progress BMS-952048 - Drug Profile Product Description Mechanism Of Action R&D Progress BMS-955829 - Drug Profile Product Description Mechanism Of Action R&D Progress BMS-984923 - Drug Profile Product Description Mechanism Of Action R&D Progress dipraglurant ER - Drug Profile Product Description Mechanism Of Action R&D Progress dipraglurant IR - Drug Profile Product Description Mechanism Of Action R&D Progress DSR-98776 - Drug Profile Product Description Mechanism Of Action R&D Progress GET-73 - Drug Profile Product Description Mechanism Of Action R&D Progress HTL-0014242 - Drug Profile Product Description Mechanism Of Action R&D Progress JNJ-46778212 - Drug Profile Product Description Mechanism Of Action R&D Progress LSN-2814617 - Drug Profile Product Description Mechanism Of Action R&D Progress mavoglurant - Drug Profile Product Description Mechanism Of Action R&D Progress PAM-12 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize mGlu5 for Rett Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize MGLUR5 for Anxiety Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress VU-0092273 - Drug Profile Product Description Mechanism Of Action R&D Progress VU-0431316 - Drug Profile Product Description Mechanism Of Action R&D Progress VU-0467558 - Drug Profile Product Description Mechanism Of Action R&D Progress Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones Featured News & Press Releases Jan 17, 2019: Experimental drug improves eye gaze behavior in fragile X syndrome Dec 13, 2018: Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept Jan 04, 2016: Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial Aug 14, 2015: Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson’s Disease Jul 22, 2015: Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation Feb 23, 2015: Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation Jan 19, 2015: Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 May 01, 2013: Addex's Dipragluant Demonstrates Dose-dependent mGlu5 Receptor Occupancy In Non-human Primate PET Study Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Indications, H1 2019 Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 (Contd..1), H1 2019 Number of Products under Investigation by Universities/Institutes, H1 2019 Products under Investigation by Universities/Institutes, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Pipeline by Addex Therapeutics Ltd, H1 2019 Pipeline by Bristol-Myers Squibb Co, H1 2019 Pipeline by Eisai Co Ltd, H1 2019 Pipeline by Eli Lilly and Co, H1 2019 Pipeline by Hua Medicine Shanghai Ltd, H1 2019 Pipeline by Johnson & Johnson, H1 2019 Pipeline by Laboratorio Farmaceutico CT Srl, H1 2019 Pipeline by Novartis AG, H1 2019 Pipeline by Park Active Molecules, H1 2019 Pipeline by Richter Gedeon Nyrt, H1 2019 Pipeline by Sosei Heptares, H1 2019 Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2019 Pipeline by Toray Industries Inc, H1 2019 Dormant Products, H1 2019 Dormant Products, H1 2019 (Contd..1), H1 2019 Dormant Products, H1 2019 (Contd..2), H1 2019 Discontinued Products, H1 2019 Discontinued Products, H1 2019 (Contd..1), H1 2019List of Figures Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Top 10 Indications, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019

Addex Therapeutics Ltd Bristol-Myers Squibb Co Eisai Co Ltd Eli Lilly and Co Hua Medicine Shanghai Ltd Johnson & Johnson Laboratorio Farmaceutico CT Srl Novartis AG Park Active Molecules Richter Gedeon Nyrt Sosei Heptares Sumitomo Dainippon Pharma Co Ltd Toray Industries Inc